Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) Factor

Trial Profile

A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) Factor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs AMG 337 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors NantPharma
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 06 Jun 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
    • 03 Jan 2018 Planned number of patients changed from 89 to 178.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top